Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2017 · 10-Q
Revenue$75.83M$75.83M+46.9% vs Q2 2016 Net Income$17.37M$17.37M+69.4% vs Q2 2016 EPS Diluted$0.32$0.32+77.8% vs Q2 2016 Operating Income$26,067,000+123.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$25,390,000+57.2% Margins · derivedOperating margin34.4%+11.8 pt vs Q2 2016
Net margin22.9%+3.0 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 3, 2017 · 34 d after period end